TLR2 regulates hair follicle cycle and regeneration via BMP signaling

  1. Luyang Xiong
  2. Irina Zhevlakova
  3. Xiaoxia Z West
  4. Detao Gao
  5. Rakhilya Murtazina
  6. Anthony Horak
  7. J Mark Brown
  8. Iuliia Molokotina
  9. Eugene A Podrez
  10. Tatiana V Byzova  Is a corresponding author
  1. Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, United States
  2. Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, United States
  3. Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, United States

Abstract

The etiology of hair loss remains enigmatic, and current remedies remain inadequate. Transcriptome analysis of aging hair follicles uncovered changes in immune pathways, including Toll-like receptors (TLRs). Our findings demonstrate that the maintenance of hair follicle homeostasis and the regeneration capacity after damage depend on TLR2 in hair follicle stem cells (HFSCs). In healthy hair follicles, TLR2 is expressed in a cycle-dependent manner and governs HFSCs activation by countering inhibitory BMP signaling. Hair follicles in aging and obesity exhibit a decrease in both TLR2 and its endogenous ligand carboxyethylpyrrole (CEP), a metabolite of polyunsaturated fatty acids. Administration of CEP stimulates hair regeneration through a TLR2-dependent mechanism. These results establish a novel connection between TLR2-mediated innate immunity and HFSC activation, which is pivotal to hair follicle health and the prevention of hair loss and provide new avenues for therapeutic intervention.

eLife assessment

Toll like receptor 2 (TLR2) signaling has traditionally been viewed a surface protein that induces innate immune responses and improves acquired immunity. Here, the authors suggest a different role for TLR2 in the hair cycle. By using a Cre reporter that is largely, but not solely active in hair follicle stem cells, the authors conditionally delete Tlr2 in mice and report that BMP signaling is sustained and hair cycle entry is delayed. Delving further, the authors identify CEP (2-ω-carboxyethyl pyrrole) as an endogenous ligand of TLR2 in hair follicle stem cell regulation. Although a role for TLR2 signaling in hair follicle stem cells is potentially novel and important, the reviewers remain in consensus that evidence presented in two significant areas continues to be incomplete: (1) where TLR2 and CEP are expressed and how specific is their expression to the hair follicle stem cells; (2) whether as the authors suggest, TLR2 functions by regulating BMP signaling in the stem cell niche of the hair follicle.

https://doi.org/10.7554/eLife.89335.3.sa0

Introduction

Hair follicles (HFs) represent one of the best examples of mini-organs with the ability to regenerate throughout life, which, in turn, relies on the proliferation and differentiation of HF stem cells (HFSCs) within hair bulge (Fuchs and Blau, 2020; Sakamoto et al., 2021). The cyclic renewal of HFs is orchestrated by the interplay between inhibitory and stimulatory signals (Plikus et al., 2011). Despite the immune privileged status of HFs, they have a unique microbiome and immune system, including resident macrophages and other immune cells (Bertolini et al., 2020; Fuchs and Blau, 2020; Paus et al., 2003). Components of the HF immune system have been implicated in regulating the HF cycle and its regeneration (Di Domizio et al., 2020; Rahmani et al., 2020). Given their exposure to pathogens, HFs are equipped with innate immune receptors, particularly Toll-like receptors (TLRs), which detect and respond to pathogens by stimulating the secretion of defensins (Di Domizio et al., 2020; Selleri et al., 2007).

TLRs play a key role in recognizing and responding to either pathogen- or damage-associated molecular patterns, mediating the cytokine response. However, the role of TLRs extends beyond this function, as they have been shown to directly promote tissue regeneration and homeostasis in multiple tissues, particularly in stem and progenitor cells. TLRs regulate hematopoietic and intestinal stem cell renewal, proliferation, and apoptosis (Nagai et al., 2006; Tomchuck et al., 2008). The role of innate immune responses in the tissue-healing benefits of stem cell therapy has been clearly demonstrated (Vagnozzi et al., 2020). Moreover, TLR activation is a critical component of the reprogramming or transdifferentiation of adult cells into pluripotency (Lee et al., 2012), emphasizing the close coordination between innate immunity, cell transformation, and regeneration.

Multiple reports connect altered HFs’ immunity to hair loss, including a breakdown of immune privilege in alopecia areata (Rahmani et al., 2020). Likewise, androgen, which is tightly linked to TLR activation, was shown to influence the innate immunity of HFs in androgenic alopecia (Sawaya, 2012). The decline of innate immunity processes due to aging or conditions like obesity is widely recognized and these conditions are causatively associated with hair thinning and loss (Andersen et al., 2016; Ghanemi et al., 2020; Palmer and Kirkland, 2016; Shaw et al., 2013). Alopecia patients often have higher body weight index and weight compared to healthy individuals (Bakry et al., 2014). Increased body weight index is linked to more significant hair loss severity in adults (Goette and Odom, 1976) and a higher prevalence of hair disorders in children and adolescents (Mirmirani and Carpenter, 2014). Mouse models support these findings, showing that activation of innate immunity through pathogen signals might lead to alopecia (Shin et al., 2018) and that high-fat diets inducing obesity cause hair thinning through HFSC depletion (Morinaga et al., 2021).

Our previous studies have shown that activating endothelial TLR2 by endogenous ligands such as CEP (a product of PUFA oxidation) promotes wound healing and tumor angiogenesis (West et al., 2010). Deletion of TLR2 from endothelial cells reduces tumor size by diminishing its vasculature (McCoy et al., 2021). In wounded skin, endothelial TLR2 is crucial for tissue regeneration through increased proangiogenic cytokine secretion (Xiong et al., 2022b). Although PUFAs have been shown to benefit hair growth by extending the anagen phase and promoting cell proliferation and hair shaft elongation (Munkhbayar et al., 2016), the role of innate immunity and in particular, TLR2 in the HF cycle remains unknown.

Using animal models and human cell lines, we show a new function of TLR2 in the HF cycle in homeostasis and HF regeneration in injury. Furthermore, we demonstrate that an endogenously produced PUFA metabolite CEP serves as a TLR2 ligand in the hair bulge, promoting hair regeneration and growth through TLR2. In conditions associated with hair loss, i.e., aging and obesity, both TLR2 and its ligand are substantially depleted in HFs.

Results

TLR2 in HF declines due to aging and obesity

To assess whether and how aging affects HF innate immunity, we analyzed available RNA sequencing data of mouse HFSCs (Doles et al., 2012). Pathway analysis revealed that innate and adaptive immunity, as well as TLR signaling, were among the top dysregulated pathways (Figure 1A). Notch, JAK-STAT, TGF-β, and Wnt, and other pathways essential for HF regeneration were also altered by aging (Figure 1A). Notably, the level of Tlr2 mRNA in HFSCs of old mice was 2-fold lower compared to young mice (Keyes et al., 2013). In addition, TLR2 at the protein level was substantially lower in 13-month-old mice compared to 2-month-old mice (Figure 1B and C).

Hair follicle stem cells (HFSCs) downregulate TLR2 in response to stress like a high-fat diet and aging.

(A) Dysregulated pathways in old vs young mouse HFSCs. The top pathways are labeled in bold. (B) Representative confocal images of telogen hair follicles from young and old mice immunostained for TLR2 and CD34 demonstrate decreased TLR2 intensity in HFSC (CD34-positive) of old mice. Scale bars are 50 μm. The middle and right panels show a magnified view of the boxed area. Scale bars are 20 μm. (C) Quantification of TLR2 fluorescent intensity in images from B showing significantly lower TLR2 expression in HFSCs from the old mice. N=6 for each group. (D) GEO2R analysis of published RNA data from sorted follicle populations in the second telogen to anagen transition demonstrates the increased level of Tlr2 mRNA accompanied by the activation of Toll-like receptors (TLRs) signaling downstream. (E) Representative confocal images showing TLR2 expression in hair follicles from mice fed with a normal diet (ND) or high-fat diet (HFD). CD34 is an HFSC marker. Scale bars are 50 μm. Magnified images demonstrate decreased TLR2 intensity in HFSC (CD34-positive) of mice after HFD. Scale bars are 20 μm. (F) Quantification of TLR2 fluorescent intensity in images from E showing significantly lower TLR2 expression in HFSCs from HFD-fed mice. N=7 and 6 for ND and HFD groups, respectively. AU, arbitrary unit. (G) Tlr2 mRNA expression in HFSCs from mice fed with ND or HFD for 4 days or 3 months. Data regenerated from published RNA sequencing dataset GSE131958. N=3 for each group. All bar graphs are mean ± s.e.m. Non-parametric Mann-Whitney test (C, G) or unpaired two-tailed t-test (F) was used to determine statistical difference. A p-value ≤ 0.05 was considered to be statistically significant.

At the same time, the normal hair cycle is marked by an increase in Tlr2 mRNA levels prior to HFSC activation during telogen, according to the analysis of existing RNA microarray data (Figure 1D; Greco et al., 2009). Tlr2 mRNA levels are highest among other Tlrs, with Tlr1 and Tlr4 mRNA showing the opposite pattern. TLR6 may act as a co-receptor for TLR2 as its expression pattern is similar. While the downstream TLR2 signaling molecules, Irak1 and Myd88, are also upregulated, mirroring the Tlr2, IRAK1 inhibitor Tollip is suppressed. Together, the results suggest the critical regulatory role of the entire TLR2/TLR6 pathway in the HF cycle.

High-fat diet-induced obesity causes hair thinning and subsequent loss (Morinaga et al., 2021). In our model, a high-fat diet causes a nearly 2-fold decline in TLR2 protein level in HFSCs, compared to normal diet-fed mice (Figure 1E and F). Further, RNA sequencing data reveal that 3 months of a high-fat diet is sufficient to reduce Tlr2 levels in HFSCs by more than 2-fold compared to control mice (Figure 1G; Morinaga et al., 2021). Thus, our results and analyses of existing datasets demonstrate that conditions causatively associated with hair thinning and loss, such as aging and obesity, result in a dramatic depletion of TLR2 in HFSCs suggesting a possible regulatory role for TLR2 in HFs.

TLR2 is upregulated during HFSC activation

The expression of TLR2 during a normal hair cycle was assessed using a previously characterized TLR2-GFP reporter mouse (Figure 2), one of the best tools for the analysis of TLRs in vivo (Price et al., 2018). The correlation between the reporter and TLR2 protein expression was confirmed (Figure 2—figure supplement 1A and B). The HF cycle was verified by H&E staining (Figure 2—figure supplement 1C). During telogen, a dormant stage for HFSCs, TLR2 was found in the bulge, secondary hair germ (sHG), dermal papilla (DP), and outer root sheath (ORS) (Figure 2A). During regenerative anagen, TLR2 expression was detected in the DP and all sHG-derived progenitor cells (Figure 2B and C) and quiescent bulge stem cells (Figure 2D and E). All cells derived from bulge stem cells (ORS) and sHG (hair shaft and inner root sheath [IRS]) were positive for TLR2 (Figure 2C). In catagen, TLR2 was abundant in the new bulge and sHG formed from ORS cells (Hsu et al., 2011; Figure 2F and G). While TLR2 was expressed in early sHG lineage (including IRS) (Figure 2C), it was absent in mature (Figure 2D and E) and regressing (Figure 2F) IRS. This shows that TLR2 is abundant in stem cells but declines upon differentiation. The second telogen’s old and new bulges expressed TLR2 (Figure 2H). TLR2 was present in sHG and DP during the second telogen (Figure 2H) and increased in the late (competent) telogen compared to the early (refractory) telogen (Figure 2—figure supplement 1D and E). The highest level of TLR2 occurred during active anagen compared to quiescent telogen and catagen (Figure 2I). Quantitative polymerase chain reaction (qPCR) revealed that the Tlr2 mRNA level in HFSCs was 5- and 2.3-fold higher in anagen than in telogen and catagen, respectively (Figure 2J). Notably, analysis of existing RNA sequencing data using FACS-sorted cells (Lorz et al., 2010) confirmed that TLR2 expression was significantly higher in HFSCs than in epidermal or non-stem cells (Figure 2K). Thus, TLR2 is enriched in HFSCs, and its expression increases during activation.

Figure 2 with 1 supplement see all
TLR2 is enriched in hair follicle stem cells (HFSCs) and is upregulated during HFSC activation.

TLR2-GFP reporter mouse skin sections were immunostained with anti-GFP to assess TLR2 expression in the hair follicles. (A) Representative confocal images of P21 first telogen hair follicle immunostained for TLR2-GFP, CD34 (bulge stem cells), P-cad (secondary hair germ [sHG]), and DAPI (nuclei). The green color in the surface rendering panel represents TLR2 expression, and other surfaces show co-localization between TLR2 and specific markers. TLR2 is present in bulge, sHG, and dermal papilla (DP) cells. P represents postnatal days. Scale bar is 10 μm. (B) TLR2-GFP in P28 anagen was co-immunostained with CD49f of basement membrane outlining the DP. Scale bar is 10 μm. (C) TLR2 is co-localized to the sHG lineage (P-cad+ layers), DP, and outer root sheath (ORS) lineage. Scale bar is 20 μm. (D) TLR2-GFP in P28 anagen was co-immunostained with CD34 in old bulge (D) and Ker5 in ORS (E) revealing TLR2 localization to the old bulge, ORS, but not inner root sheath (IRS). Scale bars are 20 μm. (F) Co-immunostaining of TLR2-GFP in P38 catagen hair follicle with Ker5 in ORS lineage cells showing co-localization of TLR2 with ORS and bulge. Scale bar is 20 μm. (G) P41 late catagen hair follicle immunostained for TLR2 and CD34 showing co-localization of TLR2 to the old bulge, new bulge, sHG, and DP. Scale bar is 20 μm. (H) P53 second telogen hair follicle immunostained for TLR2, CD34, and P-cad reveals co-localization of TLR2 to the bulge, sHG, and DP. Scale bar is 20 μm. (I) Quantification of TLR2 fluorescent intensity in bulge cells at different phases showing TLR2 upregulation in anagen. N=3 for each group. (J) Quantitative polymerase chain reaction (qPCR) analysis of Tlr2 mRNA expression in FACS-purified mouse HFSCs in anagen, telogen, and catagen. N=3 or 4 per group. (K) qPCR analysis of Tlr2 mRNA expression in mouse epidermal cells and FACS-purified HFSCs showed significantly higher Tlr2 expression in HFSCs compared with raw epidermal cells. N=6 mice per group. All bar graphs are mean ± s.e.m. Two-tailed unpaired t-test (K) or Kruskal-Wallis test with Dunn’s post hoc test (I, J) was used to determine statistical difference. A p-value ≤ 0.05 was considered to be statistically significant.

Deletion of Tlr2 in HFSCs delays anagen onset in the normal hair cycle

To address the role of TLR2 in the hair cycle, we generated an HFSC-specific inducible Tlr2 knockout (KO) mouse line (TLR2HFSC-KO) and deleted Tlr2 during the first postnatal telogen (Xiong et al., 2022b). In TLR2HFSC-KO mice, the telogen phase was substantially prolonged compared to control (Tlr2lox/lox) mice, as summarized in the schematic (Figure 3A). Melanogenesis and anagen onset are tightly coupled (Müller-Röver et al., 2001). Thus, the pink skin color at P21 marks the first postnatal telogen. The onset of anagen in control mice was indicated by the change in skin color to gray or black at P26 in control mice. TLR2HFSC-KO mice at this age did not enter anagen, as evidenced by the delayed darkening of their skin (Figure 3A–C). This was further confirmed by skin section analysis at P21, P26, and P35 (Figure 3D). At P26, control mice displayed pigmented anagen HFs with enlarged bulbs located deeply in the hypodermis, while nearly all follicles of TLR2HFSC-KO mice were ~5-fold shorter and remained in the dermis on top of adipose tissue, a characteristic of telogen. On day P35, we observe partial entrance into anagen in TLR2HFSC-KO skin while the skin color of TLR2HFSC-KO mice remains pink (Figure 3D–F). HFSCs were activated as early as at P24 in control mice based on positive Ki67 staining in sHG and bulge region (Figure 3G), while most cells in TLR2HFSC-KO sHG (Figure 3H) and bulge (Figure 3I) remained quiescent. At P25, control mice exhibited a large cluster of P-cad+ cells encapsulating DP within the transformed sHG (Figure 3K), whereas the sHG of TLR2HFSC-KO mice remained small and inactive (Figure 3J and K and Figure 3—figure supplement 1). Despite the substantial delay in anagen onset, the morphology of HFs and expression of established HFSC markers, including Ker15, CD34, and Sox9, were normal in TLR2HFSC-KO mice (Figure 3—figure supplement 2). Thus, TLR2 in HFSCs is essential for HFSC activation and progression of the hair cycle.

Figure 3 with 2 supplements see all
Deletion of TLR2 in hair follicle stem cells delays anagen onset.

(A) Schematic of RU486-mediated Cre induction and dorsal skin pigmentation change (gradient bars) in Tlr2lox/lox and TLR2HFSC-KO mice. (B) Representative images of shaved Tlr2lox/lox and TLR2HFSC-KO mice showing different phases of the hair cycle. The Tlr2lox/lox mouse transitions from telogen (pink skin) to anagen (gray/black skin) at P26 and a full hair coat is developed by P35. The TLR2HFSC-KO mouse exhibits a prolonged telogen (P21–P30–P35). Representative images of at least 10 mice in each group. (C) Bar graph showing the length of first postnatal telogen starting from P21 measured by skin color change from B. N=10 per group. (D) Representative H&E staining of dorsal skin at indicated time points showing prolonged telogen in TLR2HFSC-KO mice. Scale bars are 50 μm. (E) The length of hair follicles at P26 from images in D. 50 hair follicles from three mice per group were used for quantification. (F) Percentages of telogen or anagen hair follicles at P26 from D. N=4 mice per group. (G) Representative confocal images of P21 and P24 first telogen hair follicles from Tlr2lox/lox and TLR2HFSC-KO mice immunostained for CD34, Ki67, and DAPI. Stars label the hair shaft. Scale bars are 20 μm. (H, I) Quantification of images in G shows a diminished number of Ki67+ cells in secondary hair germ (sHG) (H) and in CD34+ bulge (I) in TLR2HFSC-KO mice compared to Tlr2lox/lox at P24. N=6 and 4 mice for Tlr2lox/lox and TLR2HFSC-KO group, respectively. (J) Representative confocal images of P21 and P25 dorsal skin sections from Tlr2lox/lox and TLR2HFSC-KO mice immunostained for P-cad and DAPI showing changes in the size of sHG. Scale bars are 20 μm. (K) Quantification of sHG size in panel K shows enlarged sHG in Tlr2lox/lox mice compared with TLR2HFSC-KO mice. N=4 mice for P25 Tlr2lox/lox, and N=5 mice for TLR2HFSC-KO. Statistical significance was determined using a non-parametric Mann-Whitney test. All data are mean ± s.e.m. A p-value ≤ 0.05 was considered to be statistically significant.

TLR2 regulates HFSC activation by interacting with BMP signaling pathway

The relationship between Wnt and BMP signaling is central to the cyclic growth of HFs (Plikus et al., 2008). Anagen initiation is triggered by Wnt/β-catenin activation, while BMP signaling suppresses HFSC activation and its reduction is necessary for HFSC activation. Indeed, during the early (refractory) phase of the second telogen, HFSCs exhibit elevated BMP signaling as evidenced by high levels of BMP7 protein and pSMAD1/5/9, downstream targets of BMP signaling, compared to the late (competent) phase (Figure 4A–D). In contrast, Bmp7 and its effectors, Id1 and Id2, are decreased during the late telogen based on our analysis of existing RNA microarray (Greco et al., 2009; Figure 4—figure supplement 1A).

Figure 4 with 1 supplement see all
TLR2 interacts with BMP pathway to regulate the hair cycle.

(A) Representative confocal images of BMP7 staining in hair follicles of dorsal skin in early (P46) and late (P69) second telogen. Scale bars are 10 μm. (B) Quantification of BMP7 fluorescent intensity from A showing diminished BMP7 expression during the second telogen from the early to late phases. N=4 per group. (C) Representative confocal images of pSMAD1/5/9 staining in hair follicles of dorsal skin in early (P46) and late (P69) second telogen. Scale bars are 10 μm. (D) Quantification of pSMAD1/5/9+ positive cells in CD34+ bulge stem cells demonstrates a decrease of pSmad1/5/9 expression in late telogen. N=4 per group. (E) Quantitative polymerase chain reaction (qPCR) analysis reveals dysregulation of BMP singling molecules in hair follicle stem cells (HFSCs) lacking Tlr2. N=4 mice for control and Bmp2, N=3 mice for Bmp7 and Bmpr1a. (F) Representative confocal images of BMP7 staining in hair follicles from Tlr2lox/lox or TLR2HFSC-KO mice. Scale bars are 10 μm. Stars label hair shaft. (G) Quantification of BMP7 fluorescent intensity from F showing higher BMP7 expression in TLR2HFSC-KO mice. N=4 per group. (H) P21 and P24 dorsal skin sections from Tlr2lox/lox and TLR2HFSC-KO mice immunostained for CD34, pSmad1/5/9, and DAPI. Scale bars are 10 μm. (I) Quantification of pSmad1/5/9+ cells in CD34+ bulge stem cells in P24 dorsal skin from H. N=4 and 5 for Tlr2lox/lox and TLR2HFSC-KO respectively. (J) Representative confocal images of dorsal skin sections from TLR2HFSC-KO mice treated with BSA or noggin immunostained for CD34, pSmad1/5/9, and DAPI. Star labels the hair shaft. Scale bars are 10 μm. (K) Quantification of pSmad1/5/9+ cells in CD34+ bulge stem cells from images in J. N=5 per group. (L) Immunostaining for Ki67 and DAPI in dorsal skin sections from TLR2HFSC-KO mice treated with BSA or noggin. Scale bars are 10 μm. (M) Quantification of images in L showing an increase in Ki67+ cells in secondary hair germ (sHG) of noggin-treated compared to BSA-treated TLR2HFSC-KO dorsal skin. N=5 per group. (N) Representative confocal images of Ki67 and DAPI immunostaining of dorsal skin sections from TLR2HFSC-KO mice treated with BSA or noggin. Arrows point to hair follicles with Ki67+ cells in the sHG. Scale bars are 20 μm. (O) Quantification of images in N showing percentages of hair follicles with Ki67+ cells in sHG. N=5 per group. (P) BSA- or noggin-treated TLR2HFSC-KO mouse dorsal skin immunostained for P-cad and DAPI. The dashed line outlines the sHG. Scale bars are 10 μm. (Q) Bar graph showing significantly larger sHG in noggin-treated TLR2HFSC-KO mice. N=5 per group. Mann-Whitney test was used to determine the statistical significance. All data are mean ± s.e.m. A p-value ≤ 0.05 was considered to be statistically significant.

To assess the possible connection between the TLR2 signaling and BMP pathway in human cells, we activated TLR2 and BMP signaling in human epidermal keratinocytes (NHEK) using a canonical TLR2 agonist (Pam3CSK4) and BMP4, respectively. As anticipated, BMP4 promoted the phosphorylation of its downstream target SMAD1/5/9. However, simultaneous co-activation of TLR2 diminished BMP4 signaling (Figure 4—figure supplement 1B and C).

Likewise, stimulation of human HFSC with canonical TLR2 agonist Pam3CSK4 promoted cell proliferation by 1.5-fold compared to controls. Notably, this effect was diminished in the presence of a TLR2-blocking antibody (Figure 4—figure supplement 1D and E). These results reveal that TLR2 activation on human HFSC augments their proliferation.

To gain a deeper understanding of TLR2’s role in HFSC activation, we profiled the transcriptome of HFSCs lacking Tlr2 expression (Figure 4—figure supplement 1F). The results showed that Tlr2 deletion dysregulated 486 genes, many of which were involved in both the hair cycle and innate immunity. The most affected pathways included innate immunity response and TLR2 signaling, with its downstream target NF-kappaB (Figure 4—figure supplement 1G). This profile somewhat resembles changes observed in aging models (Figure 1A).

BMP pathway is altered in TLR2 KO HFSCs

Since TLR2 suppresses BMP signaling and promotes HFSC proliferation, we assessed whether the delayed anagen in TLR2HFSC-KO mice might be associated with the BMP pathway. qPCR analysis reveals that several key components of the BMP pathway were dysregulated in HFSCs lacking Tlr2 (Figure 4E). Among those, the most notable changes were observed for Bmp7, which was upregulated by ~4-fold in TLR2-null HFSCs compared to controls (Figure 4E). This was substantiated by co-staining of tissue sections for BMP7 and CD34, which demonstrated an ~2-fold increase in BMP7 on HFSCs of TLR2HFSC-KO mice as compared to the control (Figure 4F and G). Activation of BMP signaling was assessed by pSMAD1/5/9 positive staining in HF. Quantification revealed an ~15-fold higher level of pSMAD1/5/9 in TLR2-null mice (TLR2KO) as compared to controls (wild type [WT]) (Figure 4—figure supplement 1H and I). The significant increase in BMP signaling observed was attributed to the absence of TLR2 in HFSCs. This was evidenced by a comparable 14-fold increase in BMP signaling in follicles of TLR2HFSC-KO mice compared to control during the first postnatal telogen phase, thereby ensuring the preservation of follicles in the dormant telogen stage (as shown in Figure 4H and I). Simultaneously, the Wnt signaling and β-catenin stabilization within HFSCs, known to trigger their activation (Deschene et al., 2014), remained unchanged between control and TLR2HFSC-KO mice (as shown in Figure 4—figure supplement 1J).

BMP antagonist rescues defects caused by the lack of HFSCs TLR2

To demonstrate that an altered BMP pathway is, indeed, responsible for the phenotype of TLR2 KO in HFSCs, we utilized intradermal injection of noggin, a well-known inhibitor of BMP signaling (Botchkarev et al., 2001; Botchkarev et al., 1999), to block the upregulated BMP signaling in TLR2HFSC-KO mice. As a result, noggin injection diminished activation of BMP signaling by >10-fold in TLR2HFSC-KO mice as assessed by pSMAD1/5/9 staining of HF (Figure 4J and K). Moreover, noggin promoted activation of TLR2HFSC-KO HFs while the HFs in BSA-treated TLR2HFSC-KO mice remained quiescent. Noggin treatment of TLR2HFSC-KO mice dramatically upregulated cell proliferation within sHG as evidenced by Ki67+ cells (Figure 4L and M), promoting ~2.5-fold increase in activated follicles (Figure 4N and O), thereby contributing to nearly 2-fold larger sHG (Figure 4P and Q) as compared to BSA-treated TLR2HFSC-KO mice. Thus, curbing suppressive BMP signaling in TLR2HFSC-KO mice can reactivate their HFs, demonstrating a causative connection between TLR2 and BMP pathways in the hair cycle.

HFSC TLR2 governs hair regeneration upon injury

High expression of TLR2 and its critical role in HFSC activation during the hair cycle prompted us to test the role of HFSCs TLR2 in an injury model where cells are more likely to be exposed to TLR2 ligands. First, we compared TLR2 levels in HFs in wounded and healthy skin using TLR2-GFP reporter mouse (Figure 5A). In healthy skin, HFSCs upregulated TLR2 during their transition from middle to late telogen (day 5 to day 10) (Figure 5B, upper panels, and gray bars in Figure 5C), consistent with RNA sequencing results (Greco et al., 2009). This increase in TLR2 precedes HFSCs activation during the normal cycle. However, in wound HFSCs, TLR2 was upregulated immediately after an injury resulting in 1.5-fold higher expression compared to normal unwounded skin (Figure 5B and C).

Hair follicle stem cell (HFSC) TLR2 is crucial for wound-induced hair follicle regeneration.

(A) Schematic of wound healing assay using TLR2-GFP reporter mouse. Full-thickness wounds on the dorsal skin of TLR2-GFP mice were created. Normal unwounded skin and the skin adjacent to the wound were harvested at different time points. (B) Representative confocal images of normal and wounded skin from TLR2-GFP mice at different time points post-injury immunostained for TLR2-GFP and CD34. Scale bars are 20 μm. (C) Quantification of TLR2 fluorescent intensity per bulge cell in hair follicles from B shows increased TLR2 level in hair follicles from wounded skin as compared to normal skin. N=3 for day 1 and day 5, and N=4 for day 10 per group. (D) Representative photographs showing hair regeneration on the dorsal skin and inner skin flaps at indicated time post-injury in wild-type (WT) and TLR2 global knockout (TLR2KO) mice. Diminished hair growth around the wound is apparent in TLR2KO skin from day 14 through 21 post-injury compared to WT skin. The inner skin flaps from TLR2KO at day 14 post-injury show an absence of pigmented hair bulbs and skin pigmentation. Scale bars are 5 mm for dorsal skin and 1 mm for inner skin flaps. (E) Quantification of the pigmented dorsal skin area around the wound from images in D shows diminished pigmentation in TLR2KO skin compared with WT skin at all time points post-injury. N=4 per group. (F) Representative confocal images of skin adjacent to wound immunostained for Ki67 and DAPI. Scale bars are 50 μm. (G) Bar graph showing diminished Ki67 fluorescent intensity in the skin adjacent to wound in TLR2KO mouse compared to WT mouse from images in F. N=4 and 7 for WT and TLR2KO respectively. (H) Representative confocal images of skin adjacent to wound immunostained for Ker17 and DAPI. Scale bars are 100 μm. (I) Quantification of hair follicle numbers from images in H reveals a significant decrease in regenerated hair follicles in TLR2KO skin compared with WT skin. N=5 and 7 for WT and TLR2KO respectively. (J) Representative photographs showing a lack of hair regeneration and skin pigmentation around the wound on the dorsal skin of TLR2HFSC-KO mice compared with Tlr2lox/lox mice on day 17, day 21, and day 24 post-injury. Scale bars are 2 mm. (K) Quantification of pigmented skin area around the wound during 14–28 days post-injury showing significantly smaller pigmented skin area in TLR2HFSC-KO mice compared with Tlr2lox/lox mice. N=4 per group. (L) Representative confocal images of wounded skin from Tlr2lox/lox and TLR2HFSC-KO mice stained for CD34 and pSmad1/5/9. Scale bars are 10 μm. (M) Quantification of images from L showing more pSmad1/5/9+ cells in TLR2HFSC-KO wounded skin. N=3 per group. Mann-Whitney test was used to determine the statistical significance. All data are mean ± s.e.m. A p-value ≤ 0.05 was considered to be statistically significant.

Hair regeneration after injury represents a substantial part of the healing process (Abbasi and Biernaskie, 2019; Chen et al., 2015; Wang et al., 2017). We next assessed the role of TLR2 using age- and gender-matched WT and TLR2KO mice. The lack of Tlr2 visibly impaired hair regeneration after wound healing (Figure 5D). On day 14 post-injury, HFs in WT mice entered precocious anagen judged by a spot of pigmented skin, which, on day 21, developed into a black hair patch (Figure 5D). In contrast, the follicles of TLR2KO mice remained quiescent lacking regenerated HFs around wounds even after 21 days post-injury (Figure 5D and E). At this point, the pigmented skin area in WT was ~9-fold larger than in TLR2KO mice. Skin flaps showed substantial pigmentation and growing hair bulbs around wounds in WT, indicative of active anagen. In contrast, the TLR2KO skin flap was devoid of pigmentation, consistent with telogen (inner skin flap in Figure 5D). Ki67 staining confirmed an increase in HFs’ activation in WT but not in TLR2KO skin (Figure 5F and G). The resulting density of regenerated HFs based on Ker17 staining in WT was 2-fold higher than in TLR2KO mice (Figure 5H and I). Most importantly, this effect was dependent on TLR2, specifically on HFSCs, since TLR2HFSC-KO mice exhibited a similar phenotype with a dramatic reduction in pigmentation and hair growth compared to control mice (Figure 5J and K). The upregulation of pSmad1/5/9 in TLR2HFSC-KO wounds compared to controls demonstrates that similar to the HF cycle scenario, increased BMP signaling might contribute to diminished HF regeneration (Figure 5L and M). Thus, the TLR2-BMP axis in HFSCs governs HF regeneration after injury.

Endogenous ligand promotes hair regeneration via TLR2 on HFSCs

One of the most important endogenous ligands for TLR2 is CEP, which is a naturally occurring product of PUFA oxidation shown to be accumulated during inflammation and wound healing (West et al., 2010; Xiong et al., 2022a). Healthy tissues are typically devoid of this product, which is mainly associated with inflammation and pathologies (Yakubenko et al., 2018). However, in contrast to other tissues, healthy HFs exhibited high levels of CEP accumulation (Figure 6A). During anagen, CEP is present within the proximal part of the follicle, while in telogen the entire follicle is encased by this PUFA metabolite (Figure 6B–E). Generation of CEP from PUFA is directly aided by myeloperoxidase (MPO) (Xiong et al., 2022a; Yakubenko et al., 2018). MPO is present in abundance in sebaceous glands, possibly as a part of immune defense (Figure 6—figure supplement 1A). Even more surprising, in contrast to other organs and tissues, CEP in HFs is substantially depleted with age (Figure 6F and G), and this decline coincides with the reduction in the regenerative potential of HFs. This is likely due to a decreased level of MPO during aging (Figure 6—figure supplement 1B and C).

Figure 6 with 1 supplement see all
Oxidation-dependent TLR2 ligand carboxyethylpyrrole (CEP) is present in hair follicles and promotes hair regeneration via hair follicle stem cell (HFSC) TLR2.

(A) Representative images of H&E and CEP immunostaining of consecutive skin sections from wild-type (WT) anagen mouse. Scale bars are 1 mm. (B) Representative confocal images of P5 WT whole-mount skin immunostained for CEP and Ker17. The merged image shows the co-localization of CEP to anagen hair follicles (Ker17+). Scale bar is 200 μm. (C) Longitudinal and cross-sections of anagen and telogen hair follicles from WT mice immunostained for CEP and Ker17. The lower left panel shows a magnified view of the boxed area. Scale bars are 100 μm for anagen, 50 μm for telogen. (D) Quantification of CEP fluorescent intensity at a different distance from the root of anagen hair follicles in longitudinal and cross-sections immunostaining images in images from C. A gradual decrease in CEP levels is observed from the proximal to the distal part of anagen hair follicles. N=50 follicles from 3 mice per group. (E) Line chart showing a sharp decrease of CEP fluorescent intensity with the distance from HF in telogen (from the lower right panel in C). N=10 follicles from 3 mice per group. (F) Representative confocal images of telogen hair follicles from young and old mice immunostained for CEP and Ker17. Scale bars are 20 μm. (G) Quantification of CEP fluorescent intensity from images in F. N=6 mice per group. (H) Representative photographs of dorsal skin (two left panels) and inner skin flaps (two right panels) from WT and TLR2KO mice after irradiation and bone marrow transplantation of WT bone marrow demonstrate an increased number of pigmented hair bulbs and skin pigmentation around wounds in CEP-treated wounds compared to control in WT mice with no differences in TLR2KO transplanted with WT bone marrow. Scale bars are 1 mm for the dorsal skin and 500 μm for the inner skin flap. (I) Quantitative results from H show an increased density of hair follicles upon CEP application around wounds of WT>WT transplanted mice with no changes in WT>TLR2KO mice. N=5 for each group. (J) Representative photographs of dorsal skin (upper panels) and inner skin flaps (lower panels) from Tlr2lox/lox and TLR2HFSC-KO mice treated with CEP show a lack of pigmentation around TLR2HFSC-KO wounds compared with Tlr2lox/lox wounds treated with CEP. The inner skin flap of TLR2HFSC-KO mice demonstrates an absence of pigmented hair bulbs after the CEP treatment. Scale bars are 3 mm. (K) Representative confocal images of skin adjacent to wound immunostained for Ker17. Scale bars are 100 μm. (L) Quantification of hair follicle numbers in images from K reveals a significant decrease in regenerated hair follicles in TLR2HFSC-KO skin compared with Tlr2lox/lox skin. N=7 for Tlr2lox/lox. N=4 for TLR2HFSC-KO. (M) Representative confocal images of skin adjacent to wound immunostained for Ki67. Scale bars are 50 μm. (N) Bar graph showing Ki67 fluorescent intensity in the skin adjacent to wound from images in M. N=7 for Tlr2lox/lox. N=4 for TLR2HFSC-KO. (O) Representative microphotographs of primary keratinocytes isolated from WT or TLR2KO mouse skin co-cultured with CEP or control (PBS or BSA). Representative images from at least three independent assays are shown. Scale bar 50 µm. (P) Cell proliferation of primary keratinocytes in O indicates increased proliferation by CEP in WT but not in TLR2KO keratinocytes. N=3 independent experiments. (Q) Quantitative polymerase chain reaction (qPCR) analyses of Nfkb2, Il1b, and Il6 mRNA levels in FACS-purified mouse HFSCs treated with BSA control or CEP. N=3 per group. (R) qPCR analyses of Bmp7 mRNA levels in FACS-purified mouse HFSCs treated with BSA control or CEP. N=3 per group. (S) Summary of the main findings of this study. Unpaired t-test (G, P) or Mann-Whitney test (I, L, N, Q, R) was used to determine the statistical significance. All data are mean ± s.e.m. A p-value ≤ 0.05 was considered to be statistically significant.

The connection between CEP levels and hair thinning and loss in aging prompted us to test whether exogenous CEP can activate TLR2 in HFSCs and stimulate their proliferation. Our in vitro experiments revealed that CEP increases the proliferation of human HFSC in a TLR2-dependent manner since the blockade of TLR2 abrogates the CEP effect (Figure 6—figure supplement 1D and E). In another model, CEP promotes cell proliferation of human hair follicle dermal papilla cells (HFDPCs) by ~2-fold compared to control (Figure 6—figure supplement 1F).

Next, we show that CEP promotes hair regeneration in injury in a TLR2-dependent manner. CEP administration promoted HF regeneration in WT wounds. However, it was ineffective in global TLR2KO mice (Figure 6—figure supplement 1H). CEP promoted a 55% increase in the number of HF and cell proliferation in WT wounds, and at the same time, there was no effect in TLR2KO wounds (Figure 6—figure supplement 1I,J).

To ensure independence from immune cells, WT and TLR2KO mice were irradiated and transplanted with WT bone marrow prior to wounding. Applying CEP on wounds in WT/WT chimeras promoted cell proliferation, thereby dramatically increasing the density of HFs (Figure 6H and I, Figure 6—figure supplement 1G). At the same time, CEP was not effective in TLR2KO/WT mice (Figure 6H and I, Figure 6—figure supplement 1G), demonstrating the TLR2-dependent mechanism.

These CEP effects were mediated by TLR2 on HFSCs. In control mice, CEP effectively initiated regeneration of HFs around the wound (Figure 6J), resulting in ~3-fold higher density of HF (Figure 6K and L) and dramatic acceleration of cell proliferation by >10-fold (Figure 6M and N) as compared to TLR2HFSC-KO mice where CEP was mainly ineffective. A similar stimulatory effect of CEP was observed in a primary keratinocyte culture (Oshimori and Fuchs, 2012). CEP dramatically promoted WT but not TLR2KO keratinocyte proliferation (Figure 6O and P). CEP was an effective stimulator of TLR2 signaling as judged by augmented Nfkb2, Il1b, and Il6 expression in HFSCs upon treatment with CEP (Figure 6Q). Consistent with the key role of BMP signaling in TLR2-dependent HF regeneration, CEP treatment suppressed inhibitory Bmp7 expression by ~2.5-fold (Figure 6R), demonstrating that endogenous and natural TLR2 ligand can counteract an inhibitory effect of BMP7 to stimulate HFSCs’ activation (Figure 6S).

Discussion

The main findings of this study are as follows: (1) Expression of TLR2 in HFSCs is decreased with aging and in a mouse model of obesity. (2) In young and healthy animals, TLR2 expression in HFs is cycle-dependent, with the highest expression in HFSCs during the initiation of the anagen phase. (3) The absence of TLR2 in HFSCs prolongs the resting phase of the hair cycle and significantly delays hair regeneration after injury. (4) TLR2 regulates the hair cycle primarily by inhibiting BMP signaling in HFSCs. (5) HFs continuously produce a metabolite of PUFAs, which acts as an endogenous TLR2 ligand and promotes hair growth through TLR2 activation in HFSCs. Besides reduced TLR2, aging is linked to low levels of its ligand in HFs. The stimulatory role of TLR2 signaling in HFs was demonstrated through both animal models and established human cell lines.

The lack of Tlr2 appears to shift the balance between activating and inhibitory cues, leading to a resting phase that is approximately three times longer. This is a substantial impact considering that there are only four to five hair cycles in a mouse lifetime (Choi et al., 2021). The decrease in both TLR2 and its ligand observed in aging and associated conditions will inevitably impede the cyclic regeneration of HFs.

The immune system was shown to play a role in the activation of HFSCs, even in the absence of inflammation (Ali et al., 2017; Castellana et al., 2014; Pinho and Frenette, 2019). TLR2 expression increases at the onset of anagen when the immune response is reduced (Paus et al., 2003) and the HF is most susceptible to pathogens. The upregulation of TLR2 in anagen may initially have a protective function. However, high TLR2 expression in undifferentiated vs. differentiated cells underscores its role in stem cell biology. TLRs, including TLR2, have been shown to play a critical role in stem cell functions in various organs (Lathia et al., 2008; Tomchuck et al., 2008; Trowbridge and Starczynowski, 2021). TLRs’ ligation and signaling can alter stem cell differentiation patterns (Collins et al., 2021; Nagai et al., 2006; Trowbridge and Starczynowski, 2021). Proinflammatory signaling can also activate HFSC proliferation, e.g., during injury (Chen et al., 2015; Wang et al., 2017). During the immune-privileged anagen phase of the hair cycle, TLR2 signaling may act as a key intrinsic factor in triggering HFSC activation.

The role of innate immunity in stem cell activation has mainly been linked to TLR3, shown to induce pluripotency in somatic cells through nuclear reprogramming (Lee et al., 2012; Sayed et al., 2015) and drive HF neogenesis after tissue damage (Nelson et al., 2015). In contrast, we show that TLR2 drives a rapid inflammatory response and regulates the normal hair cycle and HF regeneration/neogenesis in injury.

TLR2 promotes the hair cycle by inhibiting the BMP pathway, a key regulator of HFSC quiescence (Hsu et al., 2011; Kandyba et al., 2013; Plikus et al., 2008). Our study demonstrates that reducing excessive BMP signaling reactivates Tlr2-deficient HFSCs, revealing a novel link between TLR2, BMP signaling, and the hair cycle. The only known instance of immune system-mediated BMP pathway inhibition occurs during the apoptosis of bulge-associated macrophages (Castellana et al., 2014; Wang et al., 2017).

The role of TLR2 in HF regeneration in both normal hair growth and wound healing emphasizes the importance of understanding the nature of TLR2 ligands mediating these responses. At the site of injury, TLR2 can be activated by pathogens or by endogenously produced ligands, such as the oxidative product of PUFA, CEP, generated in abundance during wound healing (West et al., 2010; Yakubenko et al., 2018). CEP and TLR2 are both essential for hair regeneration, and their deficiency observed in pathologies such as aging and obesity might substantially impair hair growth. Exogenous application of CEP accelerates both wound closure (West et al., 2010) and HF regeneration through TLR2. In addition, both TLR2 and the application of CEP diminish inhibitory BMP signaling, suggesting that CEP and other TLR2 ligands could have therapeutic value for the treatment of hair loss related to burns, traumas, and other pathologies. It is intriguing that while CEP is almost exclusively generated at sites of injury and inflammation (Xiong et al., 2022a; Yakubenko et al., 2018), HFs continuously produce it, most likely by the means of MPO, an anti-bacterial enzyme, capable of generating CEP (Klebanoff et al., 2013).

Contrary to the trend observed in other tissues, where the accumulation of oxidation-generated CEP increases with aging (West et al., 2010), HFs seem to exhibit depletion of CEP with aging. This decline in CEP levels might contribute to the reduced activity of HFSCs (Fuchs and Blau, 2020).

The role of CEP in TLR2-dependent HF growth and regeneration highlights the connection between oxidative stress and regenerative processes. Sustained reactive oxygen species (ROS) play a crucial role in proper regeneration, as seen in the tail amputation of Xenopus tadpole (Love et al., 2013). ROS enhance the differentiation of hematopoietic progenitors in Drosophila (Owusu-Ansah and Banerjee, 2009) and sustain self-renewal in neural stem cells (Le Belle et al., 2011). Additionally, ROS production in the skin has been linked to the activation of HFSCs (Carrasco et al., 2015). We show the underlying mechanism for these observations, where oxidation-generated CEP triggers TLR2 activation, decreases inhibitory BMP signaling, and stimulates HF growth and regeneration. TLR2 appears to serve as a common link between oxidative stress and tissue regeneration.

To summarize, our study highlights a novel role of TLR2 in promoting tissue regeneration during normal hair growth and wound healing. The identification of an endogenous TLR2 ligand produced by HFs presents a potential target for augmenting hair regeneration in the context of injury and aging, opening up new avenues for regenerative medicine.

Materials and methods

Mice

Inducible K15-CrePR1 mice (Stock No. 005249), TLR2-GFP reporter mice (Stock No. 031822), and TLR2KO mice (Stock No. 004650) were purchased from the Jackson Laboratory. Tlr2flox/flox mice with Exon3 of the Tlr2 gene flanked by two loxP sites were described elsewhere (McCoy et al., 2021). HFSC-specific Tlr2 KO (TLR2HFSC-KO) mouse line was described previously (Xiong et al., 2022b). Briefly, Tlr2flox/flox mice were crossed with K15-CrePR1 mice to generate the inducible HFSC-specific Tlr2 KO mouse line. To induce Cre recombinase activity, RU486 (Sigma) was used topically on shaved dorsal skin (1% mixed with Neutrogena Hand Cream) or via intraperitoneal injection (10 mg/ml in corn oil, 75 µg RU486 per 1 kg body weight) during the first postnatal telogen. To block BMP signaling in mouse HFs, at first postnatal telogen after applying Ru486, 200 ng of recombinant mouse Noggin (BioLegend) reconstituted in 30 µl of PBS were injected intradermally into a dorsal skin for 3–5 consecutive days. BSA in PBS was used as vehicle control.

For high-fat diet feeding studies, male WT C57BL/6J were purchased from Jackson Laboratories (Bar Harbor, ME, USA), and at 7 weeks of age, mice were either maintained on standard rodent chow or switched to a high-fat diet containing 60% of kilocalories from fat (Research Diets D12492) for an additional 15 weeks prior to tissue collection. For all animal experiments mice were randomly assigned to the groups (if it had been required), and results were evaluated in a blinded manner. All procedures were performed according to animal protocols (00002319) approved by the Cleveland Clinic IACUC committee. All surgical procedures were performed under ketamine/xylazine anesthesia followed by subcutaneous injection of a single dose of buprenorphine SR after surgery. According to veterinarian recommendations, water with acetaminophen was provided for the next 5-7 days to minimize suffering.

Cells

Mouse keratinocytes and HFSCs were isolated from the mouse dorsal skin as described previously (Xiong et al., 2022b). Briefly, isolated dorsal skin samples were trypsinized, the epidermis was scrapped, minced, and filtered through a 70 µm cell strainer to prepare primary keratinocytes single-cell suspension. To isolate HFSC, the single-cell suspension was incubated with CD34-FITC antibody (eBioscience, 11-0341-82), Alexa 647-conjugated CD49f antibody (BD Biosciences, 562494), 7-AAD (BD Biosciences, 559925), and different fluorescence minus one was used as a control. Cells were then sorted by BD FACS Aria and analyzed by Flow Jo. All the primary cells were used within 48 hr for experiments.

Human HFDPCs, mycoplasma tested, were purchased from Cell Applications, Inc (cat.# 602-05a). Human HFSCs, mycoplasma tested, were purchased from Celprogen (cat.# 36007-08). Human epidermal keratinocytes, neonatal, pooled, mycoplasma tested, were purchased from Lonza Reagents (cat.# 192906).

Immunostaining

Request a detailed protocol

Mouse skin samples were harvested at indicated ages and fixed in 4% paraformaldehyde, kept in 30% sucrose for 2–3 days, followed by snap-freezing at –80°C in OCT (Fisher HealthCare, 4585). 10 µm skin sections were permeabilized, blocked, and incubated with primary antibodies followed by incubation with the corresponding secondary antibody, and mounted with an antifade mounting medium with DAPI (Vector Laboratories, H-1500-10). Images were captured on a Leica DM2500 confocal microscope and analyzed using Bitplane Imaris software (version 9.7.2) or ImageJ. Briefly, image z-stacks were loaded into Imaris to reconstruct three-dimensional images, and surface rendering was performed with default settings using the surface tool. The same background subtraction was performed on each z-stack. The green channel was used as a source channel to create surfaces for GFP+ cells in the area of interest in HFs, and other channels were created based on the expression of different cell markers (e.g. CD34, Ker5) in the HFs. The overlap between GFP surface and other maker surfaces was created and visualized as the co-localized area with the co-localization module. At least 10 HFs from each mouse were used for quantification.

The following antibodies or reagents were used: Ker17 (Santa Cruz Biotechnology, sc-393002), Ker15 (ABclonal, A2660), MPO (Santa Cruz Biotechnology, sc-390109), GFP (Thermo Fisher Scientific, CAB4211), TLR2 (Santa Cruz Biotechnology, sc-21759), Ki67 (Abcam, ab16667), P-cadherin (R&D Systems, AF761-SP), CEP (Pacific Immunology), pSmad1/5/9 (Cell Signaling Technology, 13820S), β-catenin (Cell Signaling Technology, 8480), CD34 (eBioscience, 11-0341-82), CD49f (BD Pharmigen, 562473), Ker5 (BioLegend, 905903), Sox9 (Cell Signaling Technology, 82,630T), BMP7 (Proteintech, 12221-1-AP), and Nile Red (ATT BioQuest, 250730). As a negative control, we used appropriate isotype match nonimmune antibody: normal mouse IgG2b-PE (Santa Cruz Biotechnology, sc-2868), normal goat IgG control (R&D, AB-108-C), normal mouse IgG (Santa Cruz Biotechnology, sc-2025), normal rabbit IgG (Cell Signaling Technology, 2729S), normal rat IgG (Santa Cruz Biotechnology, sc-2026).

Wound healing

Request a detailed protocol

Mouse wound healing procedure was performed as previously described (West et al., 2010; Xiong et al., 2022b). Briefly, an intraperitoneal injection of a ketamine/xylazine cocktail was used to anesthetize 7- to 8-week-old mice. After shaving, full-thickness wounds were made into the dorsal skin using a 6 mm biopsy punch. To examine the effect of CEP on hair regeneration after wound healing, CEP (CEP in polyethylene glycol) or vehicle (polyethylene glycol) was applied to the wounded area every day for 2 weeks. Pictures were taken at different time points to record hair regeneration around the wounded area.

Primary keratinocyte proliferation assay

Request a detailed protocol

The primary keratinocytes after isolation were plated on rat tail collagen-coated plates with Epilife medium (Gibco, MEPI500CA) supplemented with EDGS (Gibco, S0125). Cells were co-cultured with CEP or control (BSA or PBS) for 48 hr. The cell counting kit 8 (APEXbio, 269070) has been used to measure cell proliferation according to the manufacturer’s protocol.

Human HFDPC proliferation assay

Request a detailed protocol

HFDPCs (Cell Applications, Inc cat.# 602-05a) were cultured in HFDPC Growth Medium (Cell Applications, Inc cat.# 611-500) for 60 hr and then transferred into collagen-coated 48-well plate for 24 hr. After 24 hr cells were washed with 1× D-PBS and incubated in HFDPC Basal Medium contains no growth supplement (Cell Applications, Inc cat.# 610-500) for the next 24 hr. After starvation, cells were incubated with CEP 5 µM or with HFDPC Growth Medium (positive control), or in HFDPC Basal Medium (negative control) for 48 hr. Absorbance was read using cell counting kit 8 (ApexBio, cat.# K1018) on a microplate reader.

Human HFSC proliferation assay

Request a detailed protocol

Human HFSCs (Celprogen cat.# 36007-08) were cultured in HFSC Un-differentiation Media with Serum (Celprogen cat.# M36007-08US) for 48 hr and then transferred into Undifferentiated ECM 96-Well Plates (Celprogen cat.# UD36007-08-96Well) for 24 hr. After 24 hr cells were washed with 1× D-PBS and incubated in HFSC Serum Free Un-differentiation Media (Celprogen cat.# M36007-08U) overnight. After starvation, cells were incubated for 2 hr with or without TLR2 blocking antibody (Invivogen cat.# mab2-mtlr2) followed by incubation with Pam3CSK4 (Invivogen cat.# tlrl-pms) for 24 hr. HFSC Serum Free Un-differentiation Media was used as a negative control. Absorbance was read using cell counting kit 8 (ApexBio, cat.# K1018) on a microplate reader.

Human epidermal keratinocytes experiments

Request a detailed protocol

Human epidermal keratinocytes (Lonza Reagents cat.# 192906) were cultured in KGMTM Gold Keratinocyte Growth Medium (Lonza Reagents cat.# 192060) for 60 hr and then transferred into a six-well plate for 24 hr. After 24 hr media was changed, and cells were incubated with Pam3CSK4 10 µg/ml for 1 hr followed by incubation with BMP4 10 ng/ml for 1 hr.

CEP synthesis and preparation

Request a detailed protocol

The structure and synthesis of CEP have been described elsewhere (West et al., 2010). To prepare CEP for wound healing, 250 µl CEP in PBS was mixed with 1.1 g polyethylene glycol with sonication in a 45°C water bath for 15 min followed by a strong vortex to mix well. This mixture was stored at 4°C after preparation, warmed to room temperature, and mixed again before use.

Real-time qPCR

Request a detailed protocol

Total RNA from primary keratinocytes or HFSCs was isolated with RNeasy Mini Kit (QIAGEN, 74104) and reverse-transcribed into cDNA with PrimeScript RT Master Mix (Takara, RR036A). The real-time PCR was performed using iQ SYBR Green Supermix (Bio-Rad, 1708882) on the Bio-Rad cfx96 qPCR system. Target gene expression levels were normalized to internal control Rps16, and the ΔΔCt method was used to calculate fold change in gene expression. Primers can be found in Supplementary file 1.

Western blot analysis

Request a detailed protocol

Cells were lysed with RIPA Lysis and Extraction Buffer (Thermo Scientific cat.# PI89900) buffer with protease/phosphatase inhibitor cocktail. The lysate was centrifuged at 12,000×g at 4°C for 15 min, boiled with Laemmli buffer for 7 min at 95°C, and transferred to PVDF membranes (Millipore). After blocking, membranes were incubated with primary antibody at 4°C overnight followed by incubation with corresponding secondary HRP-linked antibody. The following antibodies were used for western blotting: Smad1 (D59D7) XP Rabbit mAb (Cell Signaling Technology cat.# 6944), Phospho-Smad1 (Ser463/465)/Smad5 (Ser463/465)/Smad9 (Ser465/467) (Cell Signaling Technology cat.# 13,820P), NF-κB p65 (D14E12) XP Rabbit mAb (Cell Signaling Technology cat.# 8242), Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb (Cell Signaling Technology cat.# 3033), Anti-GAPDH antibody EPR16884 Loading Control (Abcam cat.# ab181603).

BMT and wound assay

Request a detailed protocol

We performed bone marrow transplant (BMT) as previously described (West et al., 2010) Briefly, 2-month-old male WT or TLR2KO mice were lethally irradiated with 9 Gy followed by tail vein injection with 107 bone marrow cells isolated from the WT donor femurs. Eight weeks after BMT, mice were subjected to wound healing assay (described above).

RNA sequencing and data analysis

Request a detailed protocol

First telogen mouse dorsal skin was used for HFSC isolation by FACS. Total RNA was extracted using the RNeasy Mini Kit (QIAGEN, 74104). Sample quality assessment was performed on a Fragment Analyzer electrophoresis system (Agilent). Total RNA was normalized prior to oligo-dT capture and cDNA synthesis with SMART-Seq v4 (Takara). The resulting cDNA was quantified using a Qubit 3.0 fluorometer (Life Technologies). Libraries were generated using the Nextera XT DNA Library Prep kit (Illumina). Medium-depth sequencing (50 million reads per sample) was performed with a NextSeq 550 (Illumina) on a High Output flow cell using 75 base pairs, Paired-End run. Raw demultiplexed fastq paired-end read files were trimmed of adapters and filtered using the program skewer to throw out any with an average Phred quality score of less than 30 or a length of less than 36. Trimmed reads were then aligned using the HISAT2 aligner to the Mouse NCBI reference genome assembly version GRCm38 and sorted using SAMtools. Aligned reads were counted and assigned to gene meta-features using the program featureCounts as part of the Subread package. These count files were imported into the R programming language and were assessed for quality control, normalized, and analyzed using an in-house pipeline utilizing the limma-trend method for differential gene expression testing and the GSVA library for gene set variation analysis. The pathway analysis for differentially expressed genes with adjusted p-value<0.05 was performed using Enrichr web server https://maayanlab.cloud/Enrichr.

Statistical analysis

Request a detailed protocol

Statistical analyses were performed using GraphPad Prism 9. All results are mean ± s.e.m. Shapiro-Wilk normality and lognormality test was used with n≥6. For normally distributed data, we use an unpaired two-tailed t-test to compare two groups and the one-way ANOVA followed by Dunnett’s or Tukey’s post hoc analysis to compare more than two groups. For non-normally distributed data and small sample size (n<6), we appraised statistical differences with the non-parametric Mann-Whitney test to compare two sample datasets and the Kruskal-Wallis test with Dunn’s post hoc test for three or more groups. A p-value ≤ 0.05 was considered to be statistically significant. The sample size was calculated based on a significance level of 0.05 and power 80% (0.8).

Appendix 1

Appendix 1—key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Strain, strain background
(Mus musculus)
K15-CrePR1The Jackson LaboratoryCat.# 005249;
RRID:IMSRJAX:005249
RU 486-inducible Cre recombinase driven by the mouse keratin complex 1, acidic, gene 15 promoter. When induced, Cre activity is observed in epithelial stem cells in the bulge region of the hair follicle
Strain, strain background
(Mus musculus)
TLR2-GFPThe Jackson LaboratoryCat.# 031822;
RRID:IMSR_JAX:031822
Tlr2KI knock-in mice have an HA tag and an IRES-EGFP sequence placed at the 3’ end of the Toll-like receptor 2 (Tlr2) gene
Strain, strain background
(Mus musculus)
TLR2KOThe Jackson LaboratoryCat.# 004650;
RRID:IMSR_JAX:004650
Global Tlr2 KO
Strain, strain background
(Mus musculus)
Tlr2flox/floxTaconic Laboratoryc57BL/6NTacTlr2^tm3243ArteloxP sites on either side of exon 3 of the targeted TLR2 gene
Strain, strain background
(Mus musculus)
TLR2HFSC-KODescribed previously; Xiong et al., 2022bc57BL/6NTacTlr2^tm3243Arte
-B6;SJL-Tg(Krt1-15-cre/PGR)22Cot/J
RU 486-inducible hair follicle stem cells-specific Tlr2 KO
Strain, strain background
(Mus musculus)
C57BL/6JThe Jackson LaboratoryCat.# 000664
RRID:IMSR_JAX:000664
Cell line (Mus musculus)Skin keratinocytesDescribed previously; Xiong et al., 2022bFreshly isolated from the mouse dorsal skin of WT and TLR2KO mice
Cell line (Mus musculus)Hair follicle stem cellsDescribed previously; Xiong et al., 2022bFreshly isolated from the mouse dorsal skin of WT and TLR2HFSC-KO mice
Cell line (human)Hair follicle dermal papilla cellsCell Applications, IncCat.# 602-05aNormal human scalp hair follicle papilla cells
Cell line (human)Hair follicle stem cellsCelprogenCat.# 36007-08Human frontal region scalp extracted from hair follicle bulge
Cell line (human)Epidermal keratinocytes, neonatal, pooledLonza ReagentsCat.# 192906Cryopreserved normal human epidermal keratinocytes from pooled donors
AntibodyMouse monoclonal anti-keratin 17Santa Cruz BiotechnologyCat.# sc-393002- AF647;
RRID:AB_2893006
IF 1:200
AntibodyRabbit polyclonal anti-keratin 15AbclonalCat.# A2660;
RRID:AB_2764526
IF 1:100
AntibodyMouse monoclonal anti-myeloperoxidaseSanta Cruz BiotechnologyCat.# sc-390109;
RRID:AB_2892996
IF 1:100
AntibodyMouse monoclonal anti-TLR2Santa Cruz BiotechnologyCat.# sc-21759
RRID:AB_628363
IF 1:100
AntibodyRabbit polyclonal anti-GFPThermo Fisher ScientificCat.# sc-390109;
RRID:AB_10709851
IF 1:100
AntibodyRabbit monoclonal anti-Ki67AbcamCat.# ab16667;
RRID:AB_302459
IF 1:250
AntibodyGoat polyclonal anti-P-cadherinR&D SystemsCat.# AF761-SP;
RRID:AB_355581
IF 1:50
AntibodyRabbit polyclonal anti-CEPPacific ImmunologyCustomIF 1:200
AntibodyRabbit polyclonal anti-β-cateninCell Signaling TechnologyCat.# 8480;
RRID:AB_11127855
IF 1:80
AntibodyRat monoclonal anti-CD34eBioscienceCat.# 11-0341-82;
RRID:AB_465021
IF 1:200
FACS 1 µg/test
AntibodyRat monoclonal anti-CD49fBD BiosciencesCat.# 562473;
RRID:AB_11153684
IF 1:100
FACS 5 µl/test
AntibodyRabbit monoclonal anti-Sox9Cell Signaling TechnologyCat.# 82,630T;
RRID:AB_2665492
IF 1:200
AntibodyChicken polyclonal anti-keratin 5BioLegendCat.# 905903;
RRID:AB_2721742
IF 1:200
AntibodyRabbit polyclonal anti-BMP7ProteintechCat.# 12221-1-AP;
RRID:AB_2063960
IF 1:200
AntibodyRabbit monoclonal anti-pSmad1/5/9Cell Signaling TechnologyCat.# 13,820P;
RRID:AB_2493181
IF 1:200
WB 1:1000
AntibodyAnti-murine TLR2 (clone T2.5) Detection and Neutralizing mouse monoclonalInvivogenCat.# mab2-mtlr2
RRID N/A
Blocking experiment
0.66 µg/ml
AntibodySmad1 (D59D7) XP
Rabbit monoclonal
Cell Signaling TechnologyCat.# 6944WB 1:1000
AntibodyNF-κB p65 (D14E12) XP
Rabbit monoclonal
Cell Signaling TechnologyCat.# 8242WB 1:1000
AntibodyPhospho-NF-κB p65 (Ser536) (93H1) Rabbit monoclonalCell Signaling TechnologyCat.# 3033WB 1:1000
AntibodyAnti-GAPDH antibody EPR16884 Loading Control
Rabbit monoclonal
AbcamCat.# 181603WB 1:6000
AntibodyAnti-rabbit IgG, HRP-linked Antibody
goat anti-rabbit IgG Polyclonal
Cell Signaling TechnologyCat.# 7074SWB 1:3000
AntibodyNormal mouse IgG2b-PE isotype controlSanta Cruz BiotechnologyCat.# sc-2868
RRID:AB_737259
According to immune antibody concentration
AntibodyNormal goat IgG isotype controlR&DCat.# AB-108-C
RRID:AB_354267
According to immune antibody concentration
AntibodyNormal mouse IgG isotype controlSanta Cruz BiotechnologyCat.# sc-2025
RRID:AB_737182
According to immune antibody concentration
AntibodyNormal rabbit IgG isotype controlCell Signaling TechnologyCat.# 2729S
RRID:AB_1031062
According to immune antibody concentration
AntibodyNormal rat IgG isotype controlSanta Cruz BiotechnologyCat.# sc-2026
RRID:AB_737202
According to immune antibody concentration
AntibodyChicken IgY Isotype ControlNovus BiologicalsCat.# AB-101-C
RRID:AB_354263
According to immune antibody concentration
AntibodyGoat anti-Rat IgG Polyclonal (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 594InvitrogenCat.# A-11007
RRID:AB_10561522
IF 1:300
AntibodyGoat anti-Rabbit IgG Polyclonal (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488Thermo Fisher ScientificCat.# A-11008
RRID:AB_143165
IF 1:300
AntibodyGoat anti-Rat IgG Polyclonal (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488InvitrogenCat.# A-11006
RRID:AB_2534074
IF 1:300
AntibodyAlexa Fluor Plus 594 Goat anti-rabbit Polyclonal Secondary AntibodyThermo Fisher ScientificCat.# A-32740
RRID:AB_2762824
IF 1:300
AntibodyGoat anti-Mouse IgG (H+L) Cross-Adsorbed Polyclonal Secondary Antibody, Alexa Fluor 568Thermo Fisher ScientificCat. # A-11004
RRID:AB_2534072
IF 1:300
AntibodyGoat anti-Mouse IgG (H+L) Cross-Adsorbed Polyclonal Secondary Antibody, Alexa Fluor 488Thermo Fisher ScientificCat.# A-11001
RRID:AB_2534069
IF 1:300
AntibodyDonkey anti-Goat IgG (H+L) Cross-Adsorbed Polyclonal Secondary Antibody, Alexa Fluor 594Thermo Fisher ScientificCat.# A-11058
RRID:AB_142540
IF 1:300
AntibodyGoat anti-Chicken IgY (H+L) Secondary Antibody, Polyclonal Alexa Fluor 488InvitrogenCat.# A-11039
RRID:AB_2534096
IF 1:300
OtherDAPI SolutionBD BiosciencesCat#564907
RRID:AB_2869624
Fluorescent stain
IF 1:300
OtherNile RedATT BioQuestCat.# 22190Lipophilic stain
IF 10 µM
Other7-AADBD BiosciencesCat.# 559925
RRID:AB_2869266
Membrane impermeant dye 0.25 µg/test
Sequence-based reagentTLR2_FThis paperPCR primersTCTAAAGTCGATCCGCGACAT
Sequence-based reagentTLR2_RThis paperPCR primersCTACGGGCAGTGGTGAAAACT
Sequence-based reagentBMP7_FThis paperPCR primersACGGACAGGGCTTCTCCTAC
Sequence-based reagentBMP7_RThis paperPCR primersATGGTGGTATCGAGGGTGGAA
Sequence-based reagentBMP2_FThis paperPCR primersGGGACCCGCTGTCTTCTAGT
Sequence-based reagentBMP2_RThis paperPCR primersTCAACTCAAATTCGCTGAGGAC
Sequence-based reagentBMPr1A_FThis paperPCR primersAACAGCGATGAATGTCTTCGAG
Sequence-based reagentBMPr1A_RThis paperPCR primersGTCTGGAGGCTGGATTATGGG
Sequence-based reagentNFkB2_FThis paperPCR primersGGCCGGAAGACCTATCCTACT
Sequence-based reagentNFkB2_RThis paperPCR primersCTACAGACACAGCGCACACT
Sequence-based reagentIL1b_FThis paperPCR primersGCAACTGTTCCTGAACTCAACT
Sequence-based reagentIL1b_RThis paperPCR primersATCTTTTGGGGTCCGTCAACT
Sequence-based reagentIL6_FThis paperPCR primersTAGTCCTTCCTACCCCAATTTCC
Sequence-based reagentIL6_RThis paperPCR primersTTGGTCCTTAGCCACTCCTTC
Chemical compound, drugPam3CSK4InvivogenCat.# tlrl-pms10 µg/ml
Chemical compound, drugRecombinant Human BMP-4 Animal-Free ProteinR&D SystemsCat.# AFL314E-01020 ng/ml
Chemical compound, drugCEP (carboxyethylpyrrole)CustomCustomCell experiments 2.5–5 µM
Skin treatment 5 µg/ml
Software, algorithmImaris V9.7.2Bitplane
Software, algorithmImageJ, Fiji V1.53tNational Institutes of Health
Software, algorithmGraphPad Prism 9GraphPad by Dotmatics
Software, algorithmFlow JoBecton, Dickinson & Company

Data availability

The RNAseq dataset is available in the Gene Expression Omnibus GSE179300.

The following data sets were generated
The following previously published data sets were used
    1. Greco V
    2. Chen T
    3. Rendl M
    4. Schober M
    5. Amalia Pasolli H
    6. Stokes N
    7. Cruz-Racelis JD
    8. Fuchs E
    (2009) NCBI Gene Expression Omnibus
    ID GSE15185. Expression data from sorted follicle populations in the 2nd telogen to anagen transition.

References

    1. Paus R
    2. Ito N
    3. Takigawa M
    4. Ito T
    (2003) The hair follicle and immune privilege
    The Journal of Investigative Dermatology. Symposium Proceedings 8:188–194.
    https://doi.org/10.1046/j.1087-0024.2003.00807.x

Article and author information

Author details

  1. Luyang Xiong

    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Data curation, Investigation, Methodology, Writing – original draft
    Contributed equally with
    Irina Zhevlakova
    Competing interests
    No competing interests declared
  2. Irina Zhevlakova

    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Data curation, Investigation, Methodology, Writing – original draft
    Contributed equally with
    Luyang Xiong
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8596-3329
  3. Xiaoxia Z West

    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Data curation, Investigation, Methodology
    Competing interests
    No competing interests declared
  4. Detao Gao

    Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Resources, Methodology
    Competing interests
    No competing interests declared
  5. Rakhilya Murtazina

    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Present address
    Department of Biochemistry and Molecular Genetics, University of Illinois, Chicago, United States
    Contribution
    Data curation, Investigation, Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0819-9953
  6. Anthony Horak

    Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Resources
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0009-0009-2024-3679
  7. J Mark Brown

    Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2708-7487
  8. Iuliia Molokotina

    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Investigation
    Competing interests
    No competing interests declared
  9. Eugene A Podrez

    Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Resources, Supervision
    Competing interests
    No competing interests declared
  10. Tatiana V Byzova

    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States
    Contribution
    Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing
    For correspondence
    byzovat@ccf.org
    Competing interests
    Dr. Byzova has a relevant patent 9,981,018 'Compositions and Methods for Modulating Toll-Like Receptor 2 Activation'
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2615-875X

Funding

National Institutes of Health (R01 HL145536)

  • Tatiana V Byzova

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank D Nascimento and K Li for mouse colony management; T Dudiki for revision of figures; J Powers for FACS assistance; and C Nelson for proofreading. Applied Functional Genomics Core for RNA sequencing and M Kumar for data analysis. National Institutes of Health grant R01 HL145536.

Ethics

All procedures were performed according to animal protocols (00002319) approved by the Cleveland Clinic IACUC committee. All surgical procedures were performed under ketamine/xylazine anesthesia followed by subcutaneous injection of a single dose of buprenorphine SR after surgery. Water with acetaminophen was provided for the next 5-7 days to minimize suffering.

Version history

  1. Sent for peer review: June 22, 2023
  2. Preprint posted: August 16, 2023 (view preprint)
  3. Preprint posted: September 27, 2023 (view preprint)
  4. Preprint posted: January 19, 2024 (view preprint)
  5. Version of Record published: March 14, 2024 (version 1)

Cite all versions

You can cite all versions using the DOI https://doi.org/10.7554/eLife.89335. This DOI represents all versions, and will always resolve to the latest one.

Copyright

© 2023, Xiong, Zhevlakova et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 545
    Page views
  • 35
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Luyang Xiong
  2. Irina Zhevlakova
  3. Xiaoxia Z West
  4. Detao Gao
  5. Rakhilya Murtazina
  6. Anthony Horak
  7. J Mark Brown
  8. Iuliia Molokotina
  9. Eugene A Podrez
  10. Tatiana V Byzova
(2024)
TLR2 regulates hair follicle cycle and regeneration via BMP signaling
eLife 12:RP89335.
https://doi.org/10.7554/eLife.89335.3

Share this article

https://doi.org/10.7554/eLife.89335

Further reading

    1. Developmental Biology
    2. Immunology and Inflammation
    Amir Hossein Kayvanjoo, Iva Splichalova ... Elvira Mass
    Research Article Updated

    During embryogenesis, the fetal liver becomes the main hematopoietic organ, where stem and progenitor cells as well as immature and mature immune cells form an intricate cellular network. Hematopoietic stem cells (HSCs) reside in a specialized niche, which is essential for their proliferation and differentiation. However, the cellular and molecular determinants contributing to this fetal HSC niche remain largely unknown. Macrophages are the first differentiated hematopoietic cells found in the developing liver, where they are important for fetal erythropoiesis by promoting erythrocyte maturation and phagocytosing expelled nuclei. Yet, whether macrophages play a role in fetal hematopoiesis beyond serving as a niche for maturing erythroblasts remains elusive. Here, we investigate the heterogeneity of macrophage populations in the murine fetal liver to define their specific roles during hematopoiesis. Using a single-cell omics approach combined with spatial proteomics and genetic fate-mapping models, we found that fetal liver macrophages cluster into distinct yolk sac-derived subpopulations and that long-term HSCs are interacting preferentially with one of the macrophage subpopulations. Fetal livers lacking macrophages show a delay in erythropoiesis and have an increased number of granulocytes, which can be attributed to transcriptional reprogramming and altered differentiation potential of long-term HSCs. Together, our data provide a detailed map of fetal liver macrophage subpopulations and implicate macrophages as part of the fetal HSC niche.

    1. Cell Biology
    2. Immunology and Inflammation
    Cristina Cacho-Navas, Carmen López-Pujante ... Jaime Millán
    Research Article

    Epithelial intercellular adhesion molecule (ICAM)-1 is apically polarized, interacts with, and guides leukocytes across epithelial barriers. Polarized hepatic epithelia organize their apical membrane domain into bile canaliculi and ducts, which are not accessible to circulating immune cells but that nevertheless confine most of ICAM-1. Here, by analyzing ICAM-1_KO human hepatic cells, liver organoids from ICAM-1_KO mice and rescue-of-function experiments, we show that ICAM-1 regulates epithelial apicobasal polarity in a leukocyte adhesion-independent manner. ICAM-1 signals to an actomyosin network at the base of canalicular microvilli, thereby controlling the dynamics and size of bile canalicular-like structures. We identified the scaffolding protein EBP50/NHERF1/SLC9A3R1, which connects membrane proteins with the underlying actin cytoskeleton, in the proximity interactome of ICAM-1. EBP50 and ICAM-1 form nano-scale domains that overlap in microvilli, from which ICAM-1 regulates EBP50 nano-organization. Indeed, EBP50 expression is required for ICAM-1-mediated control of BC morphogenesis and actomyosin. Our findings indicate that ICAM-1 regulates the dynamics of epithelial apical membrane domains beyond its role as a heterotypic cell–cell adhesion molecule and reveal potential therapeutic strategies for preserving epithelial architecture during inflammatory stress.